Optimizing the R&D Process Using Spin-Outs: Case Studies from the Pharmaceutical Industry: R&D Spin-Outs Can Offer an Attractive Mechanism for Increasing the Effectiveness and Reach of R&D Activities While Maintaining the Focus of the Core Business. A Study of 42 Spin-Outs in the European Pharmaceutical Industry Reveals the Attributes That Lead to Successful Spin-Outs and Illustrate the Possible Advantages of Spin-Outs

By Festel, Gunter; De Cleyn, Sven H. et al. | Research-Technology Management, January-February 2011 | Go to article overview

Optimizing the R&D Process Using Spin-Outs: Case Studies from the Pharmaceutical Industry: R&D Spin-Outs Can Offer an Attractive Mechanism for Increasing the Effectiveness and Reach of R&D Activities While Maintaining the Focus of the Core Business. A Study of 42 Spin-Outs in the European Pharmaceutical Industry Reveals the Attributes That Lead to Successful Spin-Outs and Illustrate the Possible Advantages of Spin-Outs


Festel, Gunter, De Cleyn, Sven H., Boutellier, Roman, Braet, Johan, Research-Technology Management


The number of corporate R&D spin-outs in the pharmaceutical industry has increased significantly in recent years (Ramirez and Duberley 2010; Chemmanur and Yan 2004; Dewdney and Smith 1998). This may be the result of several market forces currently reshaping the industry including rising R&D costs, high failure rates for new drug candidates (Findlay 2007), and the impending expiration of a number of blockbuster patents all of which are forcing pharmaceutical companies to refocus on core activities and reduce costs (Parhankangas and Arenius 2003). In this context, spin-outs offer opportunities to enhance efficiency, divest redundant or noncore activities, and reduce costs.

Spin-outs make an independent business out of an existing part of an organization a business unit, a department, or even a project team (De Cleyn and Braet 2009). The spin-out company may take personnel, assets, intellectual property, technology, or existing products from the parent organization to support its development. Companies have various reasons for realizing a spin-out. In the case of redundant capacities or noncore activities (for instance, after a merger), a spin-out can be used to reduce costs as an alternative to closing or selling the unit (Parhankangas and Arenius 2003; Bergh and Lira 2008). A spin-out can also be used to reduce capital requirements and risk, if R&D projects are not in the strategic focus of a pharmaceutical company (Chemmanur and Yan 2004). A third possible reason is the isolation of high-risk R&D projects in non-core areas, in order to prevent it from affecting the riskiness of the core business (Arnold et al. 2010; van Gils et al. 2009).

R&D spin-outs can also be used strategically to make R&D more flexible for increased effectiveness and efficiency (Krishnaswami and Subramaniam 1999). An effective spin-out can overcome cultural hurdles to innovation, such as bureaucratic thinking, fear of cannibalism, or "not invented here" syndrome by moving the activity to a separate organization with a different culture (Bergh and Lira 2008; Jagersma and van Gorp 2003). They can more easily pick up external impulses and serve as a mechanism to explore revolutionary ideas in a setting apart from mainstream business (Parhankangas and Arenius 2003; Jagersma and van Gorp 2003).

We attempted to ascertain the real effect of R&D spinouts on drug development and on the industry in general by examining how spin-outs affected their parent companies as well as the success rates for the spin-outs themselves.

Research methodology

Based on desk research, interviews, and case studies, we sought to explore why pharmaceutical companies are increasingly engaging in spin-out activities and determine the effects, both positive and negative, of these activities for both the parent companies and the spin-outs.

This research centered on pharmaceutical spin-outs with a focus on R&D activities; spin-outs with mainly marketing or production activities were not considered. Within R&D spin-outs, we analyzed two subgroups:

1. Intellectual property-oriented spin-outs focused on creating intellectual property (IP) and even original drug candidates in different phases of the drug discovery and development process.

2. Service-oriented spin-outs providing drug discovery and development services for pharmaceutical companies based on a fee-for-service-model (for instance, lead optimization, toxicology, analytics, clinical studies, or formulation services).

Hybrid companies with both IP-oriented and service-oriented businesses were placed into one of the two groups based on their major business. Within the analysis of this study, there is no differentiation between drug discovery spin-outs (focused on basic research and drug discovery) and drug development spin-outs (focused on preclinical and clinical development).

The empirical data and case examples were obtained during two independent investigations based on desk research and interviews. …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Optimizing the R&D Process Using Spin-Outs: Case Studies from the Pharmaceutical Industry: R&D Spin-Outs Can Offer an Attractive Mechanism for Increasing the Effectiveness and Reach of R&D Activities While Maintaining the Focus of the Core Business. A Study of 42 Spin-Outs in the European Pharmaceutical Industry Reveals the Attributes That Lead to Successful Spin-Outs and Illustrate the Possible Advantages of Spin-Outs
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.